Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 8/20 | 0.34 |
| ▸ | JAK1 | P23458 | 8/20 | 0.34 |
| ▸ | JAK3 | P52333 | 8/20 | 0.34 |
| ▸ | TYK2 | P29597 | 7/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28760707 | 0.84 | MEN1 (0.35) | ALDH1A1PDK2MAPK1GAA | |
| SCHEMBL6065728 | 0.82 | SMN1; SMN2 (0.33) | ALDH1A1MAPK1JAK2JAK1JAK3 | |
| SCHEMBL4204205 | 0.82 | ALDH1A1 (0.41) | RIPK2ALDH1A1PDE4BKDM4EHPGD | |
| SCHEMBL6065937 | 0.82 | GAA (0.35) | ALDH1A1TSHRGAA | |
| SCHEMBL3116816 | 0.80 | GAA (0.35) | MAPK1GAA | |
| SCHEMBL19738133 | 0.79 | RIPK2 (0.41) | RIPK2ALDH1A1PDE4BKDM4EHPGD | |
| SCHEMBL6065935 | 0.79 | GAA (0.35) | GAA | |
| SCHEMBL4199889 | 0.77 | GAA (0.32) | GAA | |
| SCHEMBL28760706 | 0.75 | ALDH1A1 (0.36) | ALDH1A1KDM4EHPGDHSD17B10GAA | |
| SCHEMBL28760710 | 0.75 | HSP90AA1 (0.37) | ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556389-B9 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-09-09 | — | — | EP | disclosed |
| EP-1556389-B3 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2015-04-01 | — | — | EP | disclosed |
| CN-100343260-C | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2007-10-17 | — | — | CN | disclosed |
| EP-1556389-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2007-07-25 | — | — | EP | disclosed |
| US-20070037786-A1 | Cephem compounds | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7129232-B2 | For therapy of of infectious diseases | ASTELLAS PHARMA INC. (JP) | 2006-10-31 | — | — | US | disclosed |
| CN-1708502-A | Cephem compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-12-14 | — | — | CN | disclosed |
| EP-1556389-A1 | CEPHEM COMPOUNDS | Astellas Pharma Inc. (JP) | 2005-07-27 | — | — | EP | disclosed |
| US-20040132994-A1 | Cephem compounds | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039814-A1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037786-A1 | Cephem compounds | CEP170, ABCB11, SLC7A1 | RIPK2 4303/4885ALDH1A1 1158/4885PDE4B 4754/4885 |
| US-20040132994-A1 | Cephem compounds | CEP170, ABCB11, RCC2 | RIPK2 4376/4885ALDH1A1 908/4885PDE4B 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.